Join
Live feed
·
PRReleasevia Quantisnow
Cartesian Therapeutics Inc. logo

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

ByQuantisnow·Wall Street's wire, on your screen.
RNAC· Cartesian Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RNAC (Cartesian Therapeutics Inc.) and more on Quantisnow.